In the past decades, numerous tumor antigens such as CD33, CD123, CLL1, and CD38 have been explored as target antigens for AML treatment (Jin et al., 2009; Walter et al., 2012; Wang et al., 2018; Cui et al., 2021), and the clinical trials for these CAR T-cell therapies reported improved outcomes. Here, CD33 is linked to acute myeloid leukemia.